CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 163 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02655692
NCT02655692Phase 2Completed
CompareCT.gov

CAP-Ketamine for Antidepressant Resistant PTSD

VA Office of Research and Development·interventional·Posted Jan 14, 2016·Updated Jun 2, 2022

In Brief

A Phase 2 clinical trial evaluating Ketamine and Placebo/Saline for PTSD and Posttraumatic Stress Disorder. Completed, enrolled 163 participants across 3 sites.

Detailed Summary

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPTSD, Posttraumatic Stress Disorder
CountriesUnited States
CollaboratorsThe University of Texas Health Science Center at San Antonio, Brooke Army Medical Center, Minneapolis Veterans Affairs Medical Center

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 14, 2016
Enrollment StartApr 18, 2016
Primary CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.5 years ago

Interventions

Ketaminedrug

FDA approved anesthetic medication with rapid acting antidepressant effects.

Placebo/Salinedrug

This is a saline placebo/non-active solution.